Superluminal Medicines Closes $120 Million Series A RoundFinancing led by RA Capital Management with participation from Insight Partners, NVentures, Catalio Capital Management, Eli Lilly and Company, Gaingels, and Cooley LLP

Superluminal Medicines在Insight Partners、NVentures、Catalio Capital Management、Eli Lilly and Company、Gaingels和Cooley LLP的参与下，完成了由RA Capital Management牵头的1.2亿美元的A轮融资

Funds to support clinical development of lead programs and expansion of small molecule pipeline focused on high-value GPCR targetsBOSTON, September 9, 2024-- Superluminal Medicines, Inc., “The Membrane Company” using generative biology, chemistry, and machine learning approaches to revolutionize the speed and accuracy of how medicines are created, today announced the closing of a $120 million Series A funding round.

支持领先项目临床开发和小分子管道扩展的资金集中在高价值GPCR targetsBOSTON，2024年9月9日-Superluminal Medicines，Inc.，“膜公司”，使用生成生物学，化学和机器学习方法彻底改变药物产生的速度和准确性，今天宣布结束1.2亿美元的a系列融资回合。

RA Capital Management led the investment, with participation from existing investors Insight Partners, NVentures (NVIDIA’s venture capital arm), and Gaingels. New investors Catalio Capital Management, Eli Lilly and Company, and Cooley LLP joined in the financing, and Diamantis Xylas, MD of Catalio joined the Board of Directors..

RA Capital Management领导了这项投资，现有投资者Insight Partners、NVentures（NVIDIA的风险投资部门）和Gaingels参与了这项投资。新投资者Catalio Capital Management、Eli Lilly and Company和Cooley LLP加入融资，Catalio MD Diamantis Xylas加入董事会。。

The funds will support the progression of Superluminal’s lead program into clinical development and increase the number of small molecule drug discovery programs focused on high-value G protein-coupled receptor (GPCR) targets. The company’s platform rapidly creates candidate-ready compounds by utilizing a unique combination of human understanding, generative biology, chemistry, machine learning, and proprietary big data infrastructure..

这些资金将支持Superluminal的lead计划进入临床开发，并增加专注于高价值G蛋白偶联受体（GPCR）靶标的小分子药物发现计划的数量。该公司的平台通过利用人类理解、生成生物学、化学、机器学习和专有大数据基础设施的独特组合，快速创建候选化合物。。

“We are grateful to have the continued support of our renowned seed investors and prominent new investors as we rapidly progress our existing high-value programs and expand our pipeline,” said Cony D'Cruz, CEO of Superluminal Medicines. “We are advancing six small molecule programs and continue to build a discovery platform to quickly and efficiently generate therapeutics for any membrane drug target.”.

Superluminal Medicines首席执行官科尼·德克鲁斯（ConyD'Cruz）表示：“在我们迅速推进现有高价值项目并扩大渠道的过程中，我们非常感谢知名种子投资者和杰出新投资者的持续支持。”。“我们正在推进六个小分子计划，并继续建立一个发现平台，以快速有效地为任何膜药物靶标产生治疗药物。”。

“We continue to be impressed by the speed at which Superluminal has progressed its existing programs for really challenging drug targets,” said Andrew Levin, MD, PhD, Partner and Managing Director at RA Capital Management. “Superluminal’s platform and team have demonstrated success, and we are pleased to continue to support the company’s further growth and development.”.

RA Capital Management合伙人兼董事总经理安德鲁·莱文（AndrewLevin）博士说：“Superluminal在现有计划中取得的进展速度给我们留下了深刻的印象，这些计划确实具有挑战性。”。。

Superluminal’s focus is on membrane receptors that mediate cell signaling and response processes fundamental to human physiology and constitute major classes of drug targets–including GPCRs, ion channels, and transporters. GPCRs are a large family of integral membrane proteins that are drug targets for ~35% of all approved drugs.

Superluminal的重点是介导细胞信号传导和反应过程的膜受体，这些过程是人类生理学的基础，构成了主要类别的药物靶标，包括GPCR，离子通道和转运蛋白。GPCR是一大类完整的膜蛋白，是所有批准药物中约35%的药物靶标。

Yet 70% of the more than 800 GPCRs are undrugged and only 138 have experimental active-state protein structures..

然而，在800多个GPCR中，有70%是不坚固的，只有138个具有实验性活性状态蛋白质结构。。

“Our approach allows us to interrogate proteins dynamically, exploring the variety of conformations a protein can adopt, which is critical to identifying specific disease states mediated by membrane receptors,” said Mr. D'Cruz. “By understanding and leveraging these dynamic properties, we can intervene positively within the natural context of the cell and the body.”.

“我们的方法使我们能够动态地询问蛋白质，探索蛋白质可以采用的各种构象，这对于鉴定由膜受体介导的特定疾病状态至关重要，”D'Cruz先生说。“通过理解和利用这些动态特性，我们可以在细胞和身体的自然环境中进行积极干预。”。

The company’s board of directors offers a wealth of industry expertise to guide Superluminal. The board includes Andrew Levin, MD, PhD, Partner and Managing Director at RA Capital Management; Dylan Morris, Managing Director at Insight Partners; Diamantis Xylas MD, Partner and Co-Head of Investments at Catalio Capital Management and Cony D’Cruz, CEO of Superluminal Medicines..

该公司董事会提供了丰富的行业专业知识来指导超光速。董事会成员包括安德鲁·莱文（AndrewLevin），医学博士、博士，RA Capital Management合伙人兼董事总经理；Insight Partners董事总经理迪伦·莫里斯（DylanMorris）；Catalio Capital Management合伙人兼投资联席主管Diamantis Xylas MD和Superluminal Medicines首席执行官Cony D'Cruz。。

About Superluminal Medicines Inc.

关于Superluminal Medicines Inc。

Superluminal Medicines is a generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created. The company’s platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure.

Superluminal Medicines是一家产生性的生物和化学公司，开发了一条差异化的管道，彻底改变了药物创造的速度和准确性。该公司的平台利用深度生物学和化学专业知识、机器学习和专有大数据基础设施的综合结合，以前所未有的速度创建候选化合物。

The predict-design-test architecture accurately models protein shapes and designs highly selective compounds to target the precise structural change for therapeutic effect. Its discovery engine is powered by an industry-leading, pharmacokinetic and toxicology in silico prediction capability. The company’s proprietary pipeline validates its platform with initial programs focused on high-value GPCR targets.

预测设计测试体系结构准确地模拟了蛋白质的形状，并设计了高选择性的化合物，以针对治疗效果的精确结构变化。其发现引擎由业界领先的药代动力学和毒理学计算机预测能力提供动力。该公司的专有管道通过专注于高价值GPCR目标的初始计划来验证其平台。

Based in Boston, the company is backed by a strong network of investors including RA Capital Management, Insight Partners, NVentures, Catalio Capital Management, Eli Lilly and Company, Gaingels, and Cooley LLP. For more, visit www.superluminalrx.com..

该公司总部位于波士顿，拥有强大的投资者网络，包括RA Capital Management、Insight Partners、NVentures、Catalio Capital Management、Eli Lilly and company、Gaingels和Cooley LLP。有关更多信息，请访问www.superluminalrx.com。。

About RA Capital Management

关于RA资本管理

RA Capital Management is a multi-stage investment manager dedicated to evidence-based investing in public and private healthcare, life sciences, and planetary health companies. RA Capital Management forms and funds innovative companies, from private seed rounds to public follow-on financings, allowing management teams to drive value creation from inception through commercialization and beyond.

RA Capital Management是一家多阶段投资管理公司，致力于对公共和私人医疗保健、生命科学和行星健康公司进行循证投资。RA资本管理形成并资助创新公司，从私人种子轮到公共后续融资，允许管理团队从一开始就通过商业化和其他方式推动价值创造。

RA Capital Management's knowledge engine is guided by our TechAtlas internal research division, and its company creation team, RA Ventures (RAVen), offers experienced entrepreneurs a collaborative and comprehensive platform to explore the novel and the re-imagined. For more information, visit racap.com..

RA Capital Management的知识引擎由我们的TechAtlas内部研究部门指导，其公司创建团队RA Ventures（RAVen）为经验丰富的企业家提供了一个合作和全面的平台，以探索新颖和重新想象。有关更多信息，请访问racap.com。。

About Insight Partners

关于Insight Partners

Insight Partners is a global software investor partnering with high-growth technology, software, and Internet startup and Scaleup companies that are driving transformative change in their industries. As of December 31, 2023, the firm has over $80B in regulatory assets under management. Insight Partners has invested in more than 800 companies worldwide and has seen over 55 portfolio companies achieve an IPO.

Insight Partners是一家全球软件投资者，与高速增长的技术、软件和互联网初创公司以及正在推动其行业变革的规模化公司合作。截至2023年12月31日，该公司管理的监管资产超过800亿美元。Insight Partners在全球投资了800多家公司，并见证了55多家投资组合公司首次公开募股。

Headquartered in New York City, Insight has offices in London, Tel Aviv, and Palo Alto. Insight's mission is to find, fund, and work successfully with visionary executives, providing them with the right-sized, right-time practical, hands-on software expertise along their growth journey, from their first investment to IPO.

Insight总部位于纽约市，在伦敦、特拉维夫和帕洛阿尔托设有办事处。Insight的使命是找到有远见的高管，为他们提供资金，并与他们成功合作，在他们从第一次投资到首次公开募股的成长过程中，为他们提供适当规模、适当时间的实用软件专业技能。

For more information on Insight and all its investments, visit www.insightpartners.com..

有关Insight及其所有投资的更多信息，请访问www.insightpartners.com。。

Catalio Capital

加泰利奥资本

Catalio Capital Management, LP, is a multi-strategy life sciences investment firm focusing on breakthrough biomedical technology companies developing the next generation of drugs, devices, diagnostics, and data-driven insights. Catalio has partnered with over 45 world-renowned scientists with extensive academic and scientific achievements who have each also started well-established companies based on their research and to provide proprietary deal-flow and diligence to inform our investment decisions.

Catalio Capital Management，LP是一家多策略生命科学投资公司，专注于突破性的生物医学技术公司，开发下一代药物，设备，诊断和数据驱动的见解。Catalio与超过45位具有广泛学术和科学成就的世界知名科学家合作，他们各自也在研究的基础上创办了知名公司，并提供专有交易流程和尽职调查，为我们的投资决策提供信息。

The firm is headquartered in New York and has offices in London and Washington, DC. Learn more about Catalio Capital Management by visiting www.cataliocapital.com.Contact: .

该公司总部位于纽约，在伦敦和华盛顿设有办事处。有关Catalio Capital Management的更多信息，请访问www.cataliocapital.com.Contact：。。

Media Contact

媒体联系人

Janine McCargo

珍妮·麦卡戈

6 Degrees

6度

jmccargo@6degreespr.com

jmccargo@6degreespr.com